StockData
Q/C Technologies, Inc. logo

Q/C Technologies, Inc. (QCLS) shareholders

QCLSNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.33+0.01 (+4.05%)

Close on Nov 17, 2026Market cap $2.74MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
9.0%
1M of 8M shares
Institutional holders
21
6 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $5.52K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
PharmaCyte Biotech, Inc.8,475,36874.00%13D (active) amendmentNov 14, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of QCLSValueChange% of portfolio
Quinn Opportunity Partners LLC123,0241.50%$479.79K−88,3660.02%
Vanguard Capital Management LLC115,0311.40%$448.62K+77,5200.00%
Jane Street Group, LLC87,2411.07%$340.24K−38,9470.00%
Geode Capital Management, LLC70,6820.86%$275.66K+23,2920.00%
UBS Group AG58,8940.72%$229.69K−19,0950.00%
Balyasny Asset Management L.P.57,6920.70%$225.00KNew0.00%
Hrt Financial LP50,3730.62%$196.00K+27,9690.00%
ADAR1 Capital Management, LLC50,0000.61%$195.00K–0.01%
Vanguard Fiduciary Trust Co43,0530.53%$167.91K+27,4980.00%
State Street Corp25,3050.31%$98.69K+12,4000.00%
Dimensional Fund Advisors LP19,0580.23%$74.33K–0.00%
Northern Trust Corp17,9970.22%$70.19KNew0.00%
Peak6 LLC12,7780.16%$49.83KNew0.00%
Pin Oak Investment Advisors Inc3,5000.04%$14.00K–0.01%
Tower Research Capital LLC (TRC)1,0430.01%$4.07K−5500.00%
Barclays PLC9500.01%$3.71KNew0.00%
SBI Securities Co., Ltd.1000.00%$390New0.00%
BlackRock, Inc.190.00%$74–0.00%
Caitong International Asset Management Co., Ltd90.00%$35New0.00%
Jones Financial Companies Lllp20.00%$7–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026211M9.0%6 / 54 / 20M0M
Q1 2026181M7.7%7 / 51 / 70M0M
Q4 2025191M9.2%10 / 21 / 21M0M
Q3 2025110M0.2%11 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

10 funds held QCLS in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of QCLSValue% of fundAs of
Vanguard Extended Market Index Fund115,0311.40%$448.62K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund23,3530.29%$102.05K0.00%May 31, 2026
U.S. Small Cap Portfolio13,1890.16%$34.42K0.00%Jul 31, 2026
Fidelity Series Total Market Index Fund6,0460.07%$26.42K0.00%May 31, 2026
Dimensional U.S. Small Cap ETF5,5690.07%$14.54K0.00%Jul 31, 2026
Fidelity Total Market Index Fund5,2390.06%$22.89K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund2,9410.04%$12.85K0.00%May 31, 2026
Dimensional US Core Equity 1 ETF3000.00%$7830.00%Jul 31, 2026
Total Stock Market Index Trust1940.00%$7570.00%Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund-2,400-0.03%-$9.36K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Joshua SilvermanExecutive Chairman, Director116,8351.43%Oct 2, 2026
Mitchell GlassChief Medical Officer, Director12,5000.15%Apr 15, 2026
Yossef EhrlichmanChief Technology Officer––Sep 22, 2026
Charles Todd FaganChief Financial Officer––Aug 17, 2026
Ian Thomas RhodesInterim CFO––Apr 18, 2025
Chelsea Sierra VossDirector301,4553.68%May 14, 2026
Stephen FrisciaDirector25,0000.31%Apr 15, 2026
Billy Joe WhiteDirector25,0240.31%Apr 15, 2026
Bruce BernsteinDirector25,0230.31%Apr 15, 2026
PharmaCyte Biotech, Inc.10% owner––Nov 18, 2025
Gary M. Rauch–12,5000.15%Nov 14, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Joshua Silverman
Executive Chairman, Director
Oct 1, 2026Award+77,390––210,845
Joshua Silverman
Executive Chairman, Director
Jul 10, 2026Award+16,620––133,455
Joshua Silverman
Executive Chairman, Director
Apr 13, 2026Award+16,806––116,835
Joshua Silverman
Executive Chairman, Director
Apr 13, 2026Award+162,162––262,191
Chelsea Sierra Voss
Director
Mar 30, 2026Buy+1,753$3.15$5.52K61,555
Chelsea Sierra Voss
Director
Jan 16, 2026Award+212,500––214,900
Chelsea Sierra Voss
Director
Jan 16, 2026Award+25,000––239,900
Billy Joe White
Director
Nov 14, 2025Award+22,839––25,024
Mitchell Glass
Director, Chief Medical Off.
Nov 14, 2025Award+11,420––12,500
Stephen Friscia
Director
Nov 14, 2025Award+22,839––25,000
Joshua Silverman
Executive Chairman, Director
Nov 14, 2025Award+91,356––100,029
Bruce Bernstein
Director
Nov 14, 2025Award+25,000––25,000
Gary M. Rauch
–
Nov 14, 2025Award+11,420––12,500
Mitchell Glass
Director, Chief Medical Off.
Oct 3, 2025Award+1,080––1,080
Joshua Silverman
Executive Chairman, Director
Oct 3, 2025Award+8,644––8,673
Stephen Friscia
Director
Oct 3, 2025Award+2,161––2,161
Gary M. Rauch
–
Oct 3, 2025Award+1,080––1,080
Billy Joe White
Director
Oct 3, 2025Award+2,161––2,185
Paul Rivard
Chief Legal Officer
Aug 24, 2023Buy+150,000$1.11$166.50K400,000
Paul Rivard
Chief Legal Officer
Aug 17, 2023Buy+25,000$1.12$28.00K250,000
Paul Rivard
EVP of Operations, GC
Dec 8, 2022Buy+10,000$1.53$15.30K225,000
Joshua Silverman
Director
Nov 26, 2021Buy+5,000$7.55$37.75K88,775
Joshua Silverman
Director
Nov 24, 2021Buy+6,734$6.30$42.42K80,509
Joshua Silverman
Director
Nov 24, 2021Buy+3,266$7.09$23.16K83,775
Paul Rivard
EVP of Operations, GC
Nov 23, 2021Buy+15,000$6.03$90.45K215,000
Christopher C. Schreiber
Director
Apr 16, 2021Tax withholding−46,113$4.94$227.80K88,238
Christopher C. Schreiber
Director
Apr 16, 2021Option exercise+131,750––134,351
Christopher C. Chapman JR
President, Chief Med. Officer, Director
Apr 16, 2021Award+96,475––96,475
Robert C. Schroeder
Director
Apr 16, 2021Tax withholding−14,694$4.94$72.59K29,236
Robert C. Schroeder
Director
Apr 16, 2021Option exercise+43,930––43,930
Billy Joe White
Director
Apr 16, 2021Tax withholding−38,325$4.94$189.33K71,175
Billy Joe White
Director
Apr 16, 2021Option exercise+109,500––112,101
Joshua Silverman
Director
Apr 16, 2021Option exercise+109,500––112,101
Joshua Silverman
Director
Apr 16, 2021Tax withholding−38,325$4.94$189.33K71,175
Sander Gerber
10% owner
Feb 28, 2020Sale−638$2.81$1.79K240,305
Bay Capital Management LP Hudson
10% owner
Feb 27, 2020Sale−15,300$2.72$41.62K240,943
Bay Capital Management LP Hudson
10% owner
Feb 25, 2020Sale−13,000$2.92$37.96K256,243
Joshua Silverman
Director
Jan 1, 2020Option exercise+5,201––5,201
Christopher C. Schreiber
Executive Chairman, Director
Jan 1, 2020Option exercise+5,201––5,201
Billy Joe White
Director
Jan 1, 2020Option exercise+5,201––5,201
Bay Capital Management LP Hudson
10% owner
Dec 20, 2019Buy+8,000$3.02$24.16K269,243
Bay Capital Management LP Hudson
10% owner
Dec 19, 2019Buy+2,700$3.08$8.32K261,243
Bay Capital Management LP Hudson
10% owner
Dec 18, 2019Buy+7,500$3.07$23.03K258,043
Bay Capital Management LP Hudson
10% owner
Dec 17, 2019Buy+3,000$3.03$9.09K251,043
Bay Capital Management LP Hudson
10% owner
Dec 16, 2019Buy+5,000$3.07$15.35K248,043
Bay Capital Management LP Hudson
10% owner
Dec 13, 2019Buy+6,000$3.02$18.12K243,043
Bay Capital Management LP Hudson
10% owner
Dec 12, 2019Buy+20,600$2.98$61.39K237,043
Bay Capital Management LP Hudson
10% owner
Dec 11, 2019Buy+6,019$3.05$18.36K216,443
Bay Capital Management LP Hudson
10% owner
Dec 11, 2019Buy+26,406$3.10$81.86K210,424
Bay Capital Management LP Hudson
10% owner
Dec 10, 2019Buy+30,000$2.97$89.10K184,018
Bay Capital Management LP Hudson
10% owner
Dec 9, 2019Buy+19,353$2.96$57.28K104,018
Bay Capital Management LP Hudson
10% owner
Dec 9, 2019Buy+50,000$2.99$149.50K154,018
Howard Yeaton
CEO, CFO
Oct 2, 2019Award+3,750$0.42$1.58K45,000
Howard Yeaton
CEO, CFO
Aug 30, 2019Award+3,750$0.43$1.61K41,250
Howard Yeaton
CEO, CFO
Jul 31, 2019Award+3,750$0.42$1.58K37,500
Howard Yeaton
CEO, CFO
Jun 28, 2019Award+3,750$0.45$1.69K33,750
Howard Yeaton
CEO, CFO
May 24, 2019Award+7,500$0.65$4.88K30,000
Howard Yeaton
CEO, CFO
Mar 29, 2019Award+15,000$0.97$14.55K22,500
Howard Yeaton
CEO, CFO
Dec 28, 2018Award+7,500$1.27$9.53K7,500
John J. Gormally
Chief Executive Officer, Director
Oct 17, 2017Award+150,000$0.88$132.00K180,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
11.09%
1M shares short
Days to cover
6.2
At 0M shares a day
Change since last report
-8.9%
From 1M shares
Short volume, 20 days
52.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Q/C Technologies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 662,610 shares on Sep 17, 2026 over the last 90 days.

See a number that looks wrong?